Chaïbi Pascal, Merlin Laurence, Thomas Caroline, Piette François
Service de Médecine Interne Gériatrique, Hôpital Charles-Foix, 7, avenue de la République, 94200 Ivry.
Ann Med Interne (Paris). 2002 Nov;153(7):459-66.
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic disorder with serum monoclonal immunoglobulin less than 30 g/l. It preferentially affects elderly patients; MGUS prevalence is about 1% in the general population and about 10% in patients aged over 80 years. MGUS diagnosis is based on elimination of other causes of serum monoclonal immunoglobulin, particularly multiple myeloma. Within the 20 years following diagnosis of MGUS, about 25% of patients will evolve towards myeloma or other malignant lymphoproliferative disorder. No factor has been identified to date which can efficiently predict this evolution. Recent data concerning immunophenotype, cytogenetics and molecular biology of plasma cells demonstrate the link between MGUS and multiple myeloma. MGUS clearly appears now as a plasma cell monoclonal pathology with reduced malignity. Soon, new biological data would help to discriminate patients with MGUS who will remain asymptomatic life-long from those who will evolve towards malignant lymphoproliferative disorder.
意义未明的单克隆丙种球蛋白病(MGUS)是一种无症状性疾病,血清单克隆免疫球蛋白低于30g/l。它更易影响老年患者;MGUS在普通人群中的患病率约为1%,在80岁以上患者中约为10%。MGUS的诊断基于排除血清单克隆免疫球蛋白的其他病因,尤其是多发性骨髓瘤。在MGUS诊断后的20年内,约25%的患者会进展为骨髓瘤或其他恶性淋巴增殖性疾病。迄今为止,尚未发现能有效预测这种进展的因素。关于浆细胞免疫表型、细胞遗传学和分子生物学的最新数据表明了MGUS与多发性骨髓瘤之间的联系。MGUS现在显然表现为一种恶性程度降低的浆细胞单克隆病变。不久之后,新的生物学数据将有助于区分那些将终生无症状的MGUS患者和那些将进展为恶性淋巴增殖性疾病的患者。